The remarkable success of CAR-T therapy in achieving durable responses, particularly in refractory and relapsed (R/R) CD19+ leukemia and lymphoma, as well as B cell maturation antigen (BCMA)+ multiple myeloma [2,3,4,5,6,7,8,9,10,11], has underscored its potential to transform the trajectory of cancer care. Here, TNFRSF17 is linked to lymphoma.